The Quantellect read.As of Nov 19, 2026, 17 active firms cover Moderna Inc: 3 rate it Buy or better, 9 sit at Neutral, and 5 rate it Sell or worse, a neutral consensus. The target range is very wide, $18.00 to $180.00 (about 10.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $84.87 sits 57% below the current $196.76. Sentiment has cooled somewhat, with Sell ratings rising from 3 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.73 next quarter toward $-4.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Neutral
Strong Buy00%
Buy318%
Neutral953%
Sell529%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$84.87
-56.9% downside
Average target across 15 active firms as of Nov 19, 2026 vs $196.76 current
Highest Target$180.00
Average Target$84.87
Lowest Target$18.00
Detailed analyst forecasts for MRNA
Showing 1–18 of 18 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 3 of 17 active firms rate MRNA a Buy (9 Neutral, 5 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MRNA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.73
Range $-2.27 – $-0.93 · 7 analysts · -49% YoY
Next period, 7 analysts expect Moderna Inc to earn $-1.73 a share (range $-2.27 – $-0.93), versus $-3.40 a year earlier. Full-year consensus is $-7.36, growing to $-4.43 the year after.
REVENUE · NEXT QUARTER
$281.4M
Range $77.0M – $462.0M · 7 analysts · -28% YoY
Revenue is expected to reach $281.4M (range $77.0M – $462.0M), -27.7% year-over-year. Full-year consensus is $2.4B, rising to $2.7B next year.
Top analysts covering Moderna Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRNA.
#1
Luca Issi
RBC Capital · Rank #76
Neutral
$145.00-26.3% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Sell
No targeton MRNA
Overall win rate
54%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Neutral
$95.00-51.7% to target
Overall win rate
36%
+ Follow
#4
Joseph Stringer
Needham · Rank #256
Neutral
No targeton MRNA
Overall win rate
36%
+ Follow
#5
Matthew Harrison
Morgan Stanley · Rank #393
Neutral
$39.00-80.2% to target
Overall win rate
44%
+ Follow
MRNA stock forecast FAQ
What is MRNA's average 12-month price target?+
The 15 active firms with a live target average $84.87 for Moderna Inc over the next 12 months, ranging from a $180.00 high to a $18.00 low, as of Nov 19, 2026.
Is MRNA stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 17 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 9 rate it Neutral, and 5 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MRNA?+
The Street-high target is $180.00 (Argus Research), and the Street-low is $18.00 (Leerink Partners). The average of all 15 active-firm targets is $84.87.
How many active Wall Street firms cover MRNA?+
17 active firms have a recognized rating on Moderna Inc as of Nov 19, 2026, and 15 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MRNA?+
Among analysts who currently cover MRNA, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Neutral with a $145.00 target.
What is Moderna Inc's projected EPS for next quarter?+
The consensus estimate is $-1.73 per share (range $-2.27 – $-0.93) across 7 analysts. Full-year EPS is projected at $-7.36, rising to $-4.43 the following year.
How much revenue is Moderna Inc expected to report next quarter?+
Consensus revenue is $281.4M (range $77.0M – $462.0M). Full-year revenue is projected at $2.4B, growing to $2.7B next year.
Have analysts been upgrading or downgrading MRNA lately?+
As of Nov 19, 2026, 3 of 17 active firms rate MRNA a Buy (9 Neutral, 5 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.